Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Grade Last Price % Change Price Change
grade A 40.46 -0.52% -0.21
BHVN closed down 0.52 percent on Monday, December 10, 2018, on 1.89 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
3 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical BHVN trend table...

Date Alert Name Type % Chg
Dec 10 Slingshot Bullish Bullish Swing Setup 0.00%
Dec 10 Calm After Storm Range Contraction 0.00%
Dec 10 Multiple of Ten Bullish Other 0.00%
Dec 10 Wide Bands Range Expansion 0.00%
Dec 10 Overbought Stochastic Strength 0.00%
Dec 7 Wide Bands Range Expansion -0.52%
Dec 7 Overbought Stochastic Strength -0.52%
Dec 6 180 Bullish Setup Bullish Swing Setup -5.69%
Dec 6 Pocket Pivot Bullish Swing Setup -5.69%
Dec 6 Slingshot Bullish Bullish Swing Setup -5.69%

Older signals for BHVN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Is BHVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Dec 11 Biohaven Announces Proposed Public Offering of Common Shares
Dec 10 Biohaven's rimegepant shows favorable safety profile in long-term migraine study
Dec 10 Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Dec 3 Healthcare and Industrial goods dominate midday movers
Dec 3 46 Stocks Moving In Monday's Mid-Day Session
Dec 3 Biohaven Pharma up 17% on positive data on Zydis in migraine
Dec 3 Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
Nov 29 The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved
Nov 28 Biohaven forms subsidiary to commercialize products in China
Nov 28 Biohaven Announces Formation Of BioShin, A Wholly Owned Asia-Pacific Subsidiary
See more BHVN news...
Indicators
Indicator Value
52 Week High 44.28
52 Week Low 16.5
Average Volume 369,327
200-Day Moving Average 34.1398
50-Day Moving Average 36.4002
20-Day Moving Average 35.708
10-Day Moving Average 36.745
Average True Range 2.7125
ADX 27.38
+DI 28.1073
-DI 21.0835
Chandelier Exit (Long, 3 ATRs ) 35.1925
Chandelier Exit (Short, 3 ATRs ) 37.5675
Upper Bollinger Band 43.5638
Lower Bollinger Band 27.8522
Percent B (%b) 0.8
BandWidth 44.000224
MACD Line 1.0944
MACD Signal Line 0.0862
MACD Histogram 1.0082
Fundamentals Value
Market Cap 1.45 Billion
Num Shares 35.8 Million
EPS -7.54
Price-to-Earnings (P/E) Ratio -5.37
Price-to-Sales 0.00
Price-to-Book 5.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.15
Resistance 3 (R3) 45.28 43.84 44.37
Resistance 2 (R2) 43.84 42.65 43.78 44.11
Resistance 1 (R1) 42.15 41.91 41.44 42.02 43.85
Pivot Point 40.72 40.72 40.36 40.65 40.72
Support 1 (S1) 39.03 39.52 38.31 38.90 37.07
Support 2 (S2) 37.59 38.79 37.53 36.81
Support 3 (S3) 35.90 37.59 36.55
Support 4 (S4) 35.77